Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation
Status:
Withdrawn
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The number of liver transplants that can be performed is limited by the availability of
organs. Livers that are steatotic (i.e., infiltrated by triglycerides and other fatty
substances) are usually not used for transplants, due to increased risk of adverse events and
deaths post-transplant. The investigators propose administering eculizumab to patients
receiving macrosteatotic liver transplants and hypothesize that doing so will mitigate
post-surgical adverse outcomes.